The Shocking Truth" How did Zantac, once the world's most popular drug for acid reflux and heartburn, turn into a toxic ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

Shares in GSK fell around 9% this morning after a judge in a Delaware court gave the green light for tens of thousands of lawsuits claiming harm by gastrointestinal drug Zantac to proceed to trial.

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

The lawsuits arose after recipients of GSK’s heartburn drug Zantac claimed it caused cancer. Chief executive Emma Walmsey said the move to settle around 80,000 lawsuits across the US ...

Zantac was originated by GSK and launched by ... Sanofi had rights to the OTC version of the drug that was recalled in 2019 over possible contamination with NDMA, and it was also sold in generic ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

This writer thinks GSK shares appear very cheap after the Q3 results, making him wonder if now's the time for him to invest ...